Purpose: To evaluate the efficacy and safety of intracameral triamcinolone acetonide (TA) in glaucoma surgery.
Design: Prospective randomized clinical trial.
Setting: Institutional-Wills Eye Hospital.
Study population: Patients undergoing trabeculectomy (with or without cataract surgery) or tube shunt surgery.
Intervention: Patients were randomized to receive intracameral TA or balanced salt solution at the end of surgery. Follow-up time was 6 months.
Main outcome measures: Intraocular pressure, visual acuity, inflammation measured by slit-lamp examination and laser flare meter, cataract grading, bleb appearance, dry eye scores, use of supplemental medical therapy, surgical success, and rate of complications.
Results: Seventy-seven patients were enrolled in the study, including 37 in the TA group and 40 in the control group. There were no significant differences in success rates between the 2 groups (P=.60). Intraocular pressure and medication use were similar between the groups for each follow-up visit. Dry eye scores were lower in the TA group at month 1 (P=.042), while flare scores were higher in the TA group on day 1 (P=.015) but lower at month 1 (P=.044). The complication rates were higher in the TA group on day 1 (P=.04). All other outcome measures were similar for both groups.
Conclusions: Intracameral TA did not affect the success rates or change the complication rates of glaucoma surgery.
Copyright © 2014 Elsevier Inc. All rights reserved.